Protagenic Therapeutics, Inc.\new Proceeds from Convertible Debt
Protagenic Therapeutics, Inc.\new (PTIX) reported Proceeds from Convertible Debt of $542.50 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2023-03-31
- Protagenic Therapeutics, Inc.\new proceeds from convertible debt for the quarter ending 2021-12-31 was $0.00.
- Protagenic Therapeutics, Inc.\new proceeds from convertible debt for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from convertible debt for the quarter ending 2021-06-30 was $442.50K, a 14.90% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from convertible debt for the quarter ending 2021-03-31 was $100.00K, a 69.70% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from convertible debt for fiscal 2021 was $542.50K, a 53.93% decline from fiscal 2020.
- Protagenic Therapeutics, Inc.\new proceeds from convertible debt for fiscal 2020 was $1.18M, a 180.36% increase from fiscal 2019.
- Protagenic Therapeutics, Inc.\new proceeds from convertible debt for fiscal 2019 was $420.00K.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $442.50K derived: sum of 3 quarters · filed 2023-03-31 | $542.50K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $442.50K derived: sum of 2 quarters · filed 2021-11-15 | $542.50K 10-Q · filed 2021-11-15 | $542.50K derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-06-30 | $442.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $542.50K 10-Q · filed 2021-08-16 | $542.50K derived: sum of 3 quarters · filed 2021-08-16 | $870.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2021-03-31 | $100.00K 10-Q · filed 2021-05-17 | $100.00K derived: sum of 2 quarters · filed 2021-05-17 | $427.50K derived: sum of 3 quarters · filed 2021-05-17 | $947.50K derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $327.50K derived: sum of 2 quarters · filed 2021-03-25 | $847.50K derived: sum of 3 quarters · filed 2021-03-25 | $1.18M 10-K · filed 2021-03-25 |
| 2020-09-30 | $327.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $847.50K derived: sum of 2 quarters · filed 2020-11-16 | $1.18M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $850.00K 10-Q · filed 2020-08-14 | ||
| 2020-03-31 | $330.00K 10-Q · filed 2020-06-18 | |||
| 2019-12-31 | $420.00K 10-K · filed 2021-03-25 | |||
| 2011-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $4.71M 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $4.72M 10-Q/A · filed 2011-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |